Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
oleh: Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla, Haley Hedlin, Karen B. Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R. de Vries, Orlando Quintero, Kent Feng, Catherine Ley, Dean Winslow, Jennifer Newberry, Karlie Edwards, Colin Hislop, Ingrid Choong, Yvonne Maldonado, Jeffrey Glenn, Ami Bhatt, Catherine Blish, Taia Wang, Chaitan Khosla, Benjamin A. Pinsky, Manisha Desai, Julie Parsonnet, Upinder Singh
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2021-03-01 |
Deskripsi
Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duration of SARS-CoV-2 viral shedding nor improves symptoms.